Page 1 | Search Results | Blood | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-4 of 4

Sort by

Sort Order Select

Journal Articles

Dose Optimization of Inotuzumab Ozogamicin in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

Daniel J. DeAngelo, Ying Chen, Ryan D. Cassaday, Jennifer Hibma, Derek Z Yang, May Garrett, Fan Zhang, Svetoslav H Dimitrov, Erik Vandendries, Hagop M. Kantarjian

Blood (2024) 144 (Supplement 1): 732.

https://doi.org/10.1182/blood-2024-194244

Published: 2024

Journal Articles

Clinical Factors Associated with Cytokine Release Syndrome and Dosing Recommendations for Restarting Elranatamab Following an Interruption

Ruben Niesvizky, Bertrand Arnulf, Mohamad Mohty, Ajay K. Nooka, Salomon Manier, Michael Tomasson, Nizar J Bahlis, Donald Irby, Jennifer Hibma, Andrea Viqueira, Eric Leip, Alexander Lesokhin

Blood (2023) 142 (Supplement 1): 3384.

https://doi.org/10.1182/blood-2023-182166

Published: 2023

Journal Articles

Elranatamab Exposure-Efficacy Analysis in Patients with Relapsed or Refractory Multiple Myeloma: Insights from Pooled Magnetismm Studies

Hoi Kei Lon, Jennifer Hibma, Jason Williams, Diane Wang, David Gifondorwa, Wei An Ma, Lindsay King, Umberto Conte, Akos Czibere, Mohamed Elmeliegy

Blood (2023) 142 (Supplement 1): 1995.

https://doi.org/10.1182/blood-2023-190102

Published: 2023

Journal Articles

Dose Optimization to Mitigate the Risk of CRS with Elranatamab in Multiple Myeloma

Mohamed Elmeliegy, Andrea Viqueira, Erik Vandendries, Anne Hickman, Jennifer Hibma, Hoi-Kei Lon, Joseph Piscitelli, Pooneh Soltantabar, Diane Wang, Sibo Jiang, Gregory Finn, Akos Czibere

Blood (2022) 140 (Supplement 1): 7174–7175.

https://doi.org/10.1182/blood-2022-169971

Published: 2022